Drugs / AVM0703
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04329728 | Nov 2020 → Nov 2027 expected | lymphoma | AVM Biotechnology Inc | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05974410 | — | Hodgkins lymphoma, brain neoplasm, breast cancer, desmoplastic small round cell tumor +10 | AVM Biotechnology Inc | Available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04366115 Comparator | Dec 2026 → Dec 2031 expected | COVID-19, acute respiratory distress syndrome, influenza | AVM Biotechnology Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVM0703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05974410 ↗ |
| Modality | Small molecule | “small molecule immunomodulatory drug” NCT05974410 ↗ |
| Route | Intravenous | “AVM0703 administered as a single intravenous (IV) infusion” NCT04329728 ↗ |